Skip to content
DataLookout
Menu

NCT07914855

Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 1 with changes below, 1 re-verified with no change.

  1. Study First Submitted

Endpoints

Primary

Fluorodeoxyglucose (FDG) positron emission tomography metabolic response rate
Timeframe: Up to 12 months

Secondary (9)

Incidence of adverse events
Overall response rate
Radiographic progression-free survival (PFS)
Prostate specific antigen (PSA)-PFS
Duration of response (DOR)
Show 4 moreShow less
Time to PSA progression
Overall survival (OS)
Tumor response signatures
DSP-5336 (enzomenib) pharmacokinetics (PK)

Arms and interventions

Treatment (androgen deprivation therapy, enzomenib)Experimental

Patients continue to receive usual androgen deprivation therapy per standard of care. Patients receive enzomenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, FDG PET/CT, PSMA PET/CT, CT, bone scan and tissue biopsy throughout the study.

Drugs: Antiandrogen Therapy, Enzomenib

Procedures: Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, FDG-Positron Emission Tomography, PSMA PET Scan

Other: Fludeoxyglucose F-18